



Horizon Therapeutics plc Announces Agenda for Virtual R&D Day for Investors and Analysts on Sept. 29, 2021

September 23, 2021

-- Event Begins at 9 a.m. ET --

DUBLIN--(BUSINESS WIRE)--Sep. 23, 2021-- Horizon Therapeutics plc (Nasdaq: HZNP) today announced the agenda for its virtual R&D Day for investors and analysts on Sept. 29, 2021. During the event, Horizon's R&D leadership, executives and key opinion leaders will discuss its expanded pipeline and participate in three Q&A sessions.

The virtual event will be held from 9 a.m. to 12:30 p.m. Eastern Time and may be accessed at <https://horizonrdinvestorday.stagepro.io/>. Please connect at least 15 minutes prior to the live webcast to register and ensure adequate time for any software download that may be needed to access the event.

Horizon's R&D Day investor event will cover the following topics:

Horizon's Vision and Strategy

Tim Walbert, chairman, president and chief executive officer

Horizon's R&D Strategy

Elizabeth H.Z. Thompson, Ph.D., executive vice president, research and development

Srini Ramanathan, Ph.D., senior vice president, research and development sciences

HZN-7734: First and Only Plasmacytoid Dendritic Cell Deleter in Clinical Development

Bill Rees, Ph.D., vice president, translational sciences

Theresa Podrebarac, M.D., M.Sc., senior vice president, clinical development

HZN-4920: CD40L Antagonist Designed to Block a Central Pathway Involved in Many Autoimmune and Inflammatory Diseases

Bill Rees, Ph.D., vice president, translational sciences

Theresa Podrebarac, M.D., M.Sc., senior vice president, clinical development

HZN-825 LPAR₁ Antagonist with Early Signals of Benefit in Fibrotic Diseases, Areas of High Unmet Need

Srini Ramanathan, Ph.D., senior vice president, research and development sciences

Dinesh Khanna, M.D., M.B.B.S., M.Sc., professor, Institute for Healthcare Policy and Innovation, University of Michigan

Martin Kolb, M.D., Ph.D., director of the division of respiratory, department of medicine, McMaster University

UPLIZNA[®] (inebilizumab-cdon): Next-Generation B-Cell Deleter with a Novel, Targeted Approach

Kristina Patterson, M.D., Ph.D., medical director, neuroimmunology

Theresa Podrebarac, M.D., M.Sc., senior vice president, clinical development

TEPEZZA[®] (teprotumumab-trbw): Building Evidence to Help Treat More Patients with Chronic Thyroid Eye Disease (TED)

Bobby S. Korn, M.D., Ph.D., FACS, professor of ophthalmology and plastic surgery, University of California, San Diego

Closing Remarks

Tim Walbert, chairman, president and chief executive officer

About Horizon

Horizon is focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune and severe inflammatory diseases. Our pipeline is purposeful: we apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. For more information on how we go to incredible lengths to impact lives, please visit www.horizontherapeutics.com and follow us on [Twitter](#), [LinkedIn](#), [Instagram](#) and [Facebook](#).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20210923005292/en/): <https://www.businesswire.com/news/home/20210923005292/en/>

Investors:

Tina Ventura

Senior Vice President, Investor Relations

investor-relations@horizontherapeutics.com

Ruth Venning

Executive Director, Investor Relations

investor-relations@horizontherapeutics.com

U.S. Media:

Geoff Curtis

Executive Vice President, Corporate Affairs & Chief Communications Officer

media@horizontherapeutics.com

Ireland Media:

Ray Gordon

Gordon MRM

ray@gordonmrm.ie

Source: Horizon Therapeutics plc